Musculoskeletal Diseases: From Molecular Basis to Therapy (Volume II)
Belluzzi E., Pozzuoli A., Ruggieri P.
Prospective Study, published in Biomedicines (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Biomedicines (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40722792
- PMCID
- PMC12293032
- DOI
- 10.3390/biomedicines13071722
Abstract (original English)
Musculoskeletal diseases (MSDs) are among the leading causes of disability worldwide, placing a significant burden on healthcare systems and reducing patients' quality of life [...].
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.